Background. Diabetic retinopathy (DR) has been primarily indicated to cause vision impairment and blindness, while no studies have focused on the cost-utility of telemedicine-based and community screening programs for DR in China, especially in rural and urban areas, respectively.Methods. We developed a Markov model to calculate the cost-utility of screening programs for DR in DM patients in rural and urban settings from the societal perspective. The incremental cost-utility ratio (ICUR) was calculated for the assessment.Results. In the rural setting, the community screening program obtained 1 QALY with a cost of $4179 (95% CI 3859 to 5343), and the telemedicine screening program had an ICUR of $2323 (95% CI 1023 to 3903) compared with no screening, both of which satisfied the criterion of a significantly cost-effective health intervention. Likewise, community screening programs in urban areas generated an ICUR of $3812 (95% CI 2906 to 4167) per QALY gained, with telemedicine screening at an ICUR of $2437 (95% CI 1242 to 3520) compared with no screening, and both were also cost-effective. By further comparison, compared to community screening programs, telemedicine screening yielded an ICUR of 1212 (95% CI 896 to 1590) per incremental QALY gained in rural setting and 1141 (95% CI 859 to 1403) in urban setting, which both meet the criterion for a significantly cost-effective health intervention.Conclusions. Both telemedicine and community screening for DR in rural and urban settings were cost-effective in China, and telemedicine screening programs were more cost-effective.
基金:
Major Innovation Platform of Public Health & Disease Control and Prevention, Renmin University of China; Beijing Nova Program [Z191100001119072]
语种:
外文
被引次数:
WOS:
第一作者:
第一作者机构:[1]Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Inst Ophthalmol,Beijing Tongren Eye Ctr, Beijing, Peoples R China
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Ophthalmol & Visual Sci, Beijing Inst Ophthalmol,Beijing Tongren Eye Ctr, Beijing, Peoples R China[4]Peking Univ, Natl Inst Hlth Data Sci, Beijing, Peoples R China[5]Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China[6]Beijing Inst Technol, Sch Informat & Elect, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Zhang Yue,Bai Weiling,Li Ruyue,et al.Cost-Utility Analysis of Screening for Diabetic Retinopathy in China[J].HEALTH DATA SCIENCE.2022,2022:doi:10.34133/2022/9832185.
APA:
Zhang, Yue,Bai, Weiling,Li, Ruyue,Du, Yifan,Sun, Runzhou...&Liu, Hanruo.(2022).Cost-Utility Analysis of Screening for Diabetic Retinopathy in China.HEALTH DATA SCIENCE,2022,
MLA:
Zhang, Yue,et al."Cost-Utility Analysis of Screening for Diabetic Retinopathy in China".HEALTH DATA SCIENCE 2022.(2022)